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http://dx.doi.org/10.1016/j.bbmt.20BK virus (BKV) infection is associated with hemorrhagic cystitis (HC) in hematopoietic stem cell trans-
plantation (HSCT) recipients and nephropathy after kidney transplantation. We assessed the association
between BKV and kidney and bladder complications in children developing HC by retrospectively reviewing
221 consecutive pediatric allogeneic HSCT recipients at the Children’s Hospital of Philadelphia from 2005 to
2011. We included all patients with BKV PCR testing performed for clinical indication from day 0 until 1 year
post-HSCT (N ¼ 68). We assessed the association of any BKV infection (urine and/or blood) or peak BK viremia
 10,000 copies/mL (high viremia) with severe HC (deﬁned as grade IVdbladder catheterization or surgical
intervention); the need for dialysis; serum creatinineeestimated glomerular ﬁltration rate at the time of BKV
testing, day 100, and day 365; and death. Children with high viremia more likely developed severe HC
compared with those with peak viremia < 10,000 copies/mL (21% versus 2%; P ¼ .02). BKV infection of the
blood or urine was not associated with the need for dialysis, change in estimated glomerular ﬁltration rate, or
mortality. BKV infection is common after pediatric allogeneic HSCT, and plasma testing in those with HC may
predict patients who will develop severe bladder injury.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION BKV infection and kidney disease in HSCT recipients has not
BK virus (BKV) is a DNA polyoma virus that infects most
of the general population, with seroprevalance rates
approaching 90% by 10 years of age [1]. After primary infec-
tion, the virus remains dormant in the uroepithelial cells of
the kidney and bladder [2]. Clinical disease from BKV infec-
tion is almost exclusively seen in immunocompromised
patients, particularly kidney transplantation and hemato-
poietic stem cell transplantation (HSCT) recipients [3,4]. After
HSCT, BKV infection identiﬁed in the urine (viruria) and/or
blood (viremia) may be associated with hemorrhagic cystitis
(HC) [5,6]. BKV viremia after renal transplantation contrib-
utes to kidney injury (nephropathy), typically in the absence
of symptomatic HC, and may lead to allograft loss [2].
HC is a frequent complication of allogeneic HSCT, occur-
ring in up to 25% of patients [4]. HC can be associated with
signiﬁcant morbidity and mortality, including prolonged
hospitalization, invasive surgical procedures to manage
bleeding, and acute kidney injury from urinary tract ob-
struction [7-9]. Early-onset HC is secondary to direct toxicity
from the preparative conditioning regimen [3]. Late-onset
HC typically occurs after the ﬁrst week after trans-
plantation and is associated with infections, such as BKV, or,
less commonly, adenovirus and cytomegalovirus (CMV) [9].
Kidney and bladder injury are common complications
after HSCT, and chronic kidney disease is often considered
idiopathic in this population [10]. The relationship betweenedgments on page 1706.
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may also contribute to nephropathy in the native kidneys of
HSCT and nonrenal solid-organ transplantation recipients,
even in the absence of HC [11-14]. Only 2 prior studies in
patients undergoing HSCT, 1 in adults [15] and the other in
children [16], investigated if BKV infection identiﬁed in the
blood (viremia) is a risk factor for intrinsic kidney injury. Our
objective was to assess the impact of BKV infection on
the severity of genitourinary outcomes in children under-
going HSCT for predominately malignant indications. We
hypothesized that BK viremiawould be associatedwithmore
severe kidney and bladder injury in children undergoing
allogeneic HSCT.
METHODS
We reviewed the records of all children undergoing allogeneic HSCT at
the Children’s Hospital of Philadelphia from January 2005, when BKV PCR
testing became clinically available, until March 2012. We included any
patient with BKV PCR testing of blood or urine performed from day 0 until
1 year post-HSCT. We excluded patients undergoing autologous HSCT and
any patient without at least 1 blood or urine BK PCR test. The protocol was
approved by our center’s institutional review board.
At our institution, BKV testing is performed only for a clinical indication
(no routine screening) and almost exclusively in patients with concern for
HC due to gross hematuria and/or urinary symptoms. Testing is typically
performed ﬁrst with a urine PCR. Subsequent plasma testing is also ordered
at the discretion of the attending physician but usually for those patients
with a positive urine PCR or persistent symptoms.
Separate BKV exposures were considered. First, patients with a positive
BKV urine PCR (viruria, > 0 copies/mL) were compared with those without
viruria. Additionally, subjects with plasma PCR testing were compared using
the quantitative value of their peak level of viremia during the ﬁrst year after
transplantation. Using viral PCR thresholds reported in kidney trans-
plantation patients with BK viremia [4] and HSCT recipients with adeno-
viremia [17], subjects were categorized as having a peak plasma viral load
 10,000 copies/mL (high viremia) or <10,000 copies/mL (low viremia).
Because viremia is rare in patients without viruria, patients with negativeTransplantation.
Figure 1. Flowchart depicting categorization of subjects based on BKV urine and plasma testing.
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viremia group.
The following separate outcomes were assessed: percent change in
baseline serum creatinine-based estimated glomerular ﬁltration rate (eGFR)
at day 100, day 365, and the time of BKV infection; the need for dialysis at
any point between day 0 and the end of follow-up; and the severity of HC.
Overall survival and transplantation-related mortality were also considered
as outcomes. Transplantation-related mortality was deﬁned as nonrelapse
death.
Each subject’s mean serum creatinine level was recorded during the 14
days before the initiation of the conditioning regimen (baseline) and during
the 14-day periods around day 100 and day 365. The creatinine on the ﬁrst
day of BKV testing was also obtained from the medical record. The eGFR was
calculated with the modiﬁed Schwartz formula [18] (.413  height [cm]/
serum creatinine [mg/dL]), using the height at time of initiation of the
conditioning regimen.
Urinalyses and the clinical record from the time of BKV testing were
reviewed, and the severity of HC was classiﬁed according to published
criteria: grade 0, no hematuria; grade I, microscopic hematuria; grade II,
gross hematuria; grade III, gross hematuria with clots; grade IV, need for
catheterization or surgical intervention [19,20]. We deﬁned “severe HC” as
patients with grade IV disease.
Patients with positive CMV or adenovirus blood PCR testing
(>0 copies/mL) within 2 weeks before or after BKV testing were classiﬁed as
having a concomitant viral infection. At our institution, blood CMV and
adenovirus PCR testing are sent for clinical indication, weekly surveillance in
all recipients of allogeneic T celledepleted or cord blood grafts, and in all
patients receiving alemtuzumab. In addition, CMV screening occurs in all
recipients of matched related donor transplantations if either the donor or
recipient is CMV positive.
BKV testing was performed using a real-time TaqMan quantitative PCR
assay with nucleic acid primer/probe pairs speciﬁc for conserved regions of
the BK virus genome (Roche Molecular Systems, Pleasanton, California). In
our hospital’s clinical laboratory, the assay can quantitate the viral load in
urine or blood above a lower threshold of 302 copies/mL. Hospital protocol
is to ﬁrst test for BKV using a qualitative PCR, followed by quantitative
testing for initial positive results.
The dates and viral load of all BKV quantitative measurements in blood
and urine were recorded from the start of conditioning until 1 year after
transplantation. Baseline demographic and transplantation data were
collected, including age, gender, underlying condition, conditioning
regimen, stem cell source, donor type, time to neutrophil and platelet
engraftment, incidence of veno-occlusive disease, incidence and grading of
acute and chronic graft-versus-host disease (GVHD), and survival up to 1
year or at time of last follow-up. In addition, we reviewed documentation
regarding medical and surgical management of HC and the need for dialysis.When BKV infectionwas treated with cidofovir, it was administered at a low
dose of .25 mg/kg every 2 weeks [21].
Because the patient population in this study was heterogeneous in
terms of underlying disease, the transplantation regimen was highly vari-
able. For patients receiving myeloablative conditioning for hematologic
malignancy, the conditioning regimen consisted of either busulfan/cyclo-
phosphamide or cyclophosphamide/total body irradiation, with or without
thiotepa. A subset of patients also received horse antithymocyte globulin.
Recipients of reduced-intensity conditioning regimens generally received
ﬂudarabine, melphalan, and alemtuzumab. Infectious prophylaxis varied by
risk factors and graft type but in general included acyclovir for herpes
simplex virus/varicella zoster virus, intravenous immune globulin for those
at risk of CMV, foscarnet in patients at high risk for CMV, ﬂuconazole, and
oral gentamicin/amoxicillin for gut decontamination. All patients received
a calcineurin inhibitor for GVHD chemoprophylaxis (infusional cyclosporine
followed by enteral tacrolimus). Additional GVHD prophylaxis included
short-course methotrexate in bone marrow recipients, corticosteroids in
cord blood recipients, mycophenolate mofetil in reduced-intensity condi-
tioning recipients, and partial ex vivo T cell depletion in growth fac-
toremobilized peripheral blood stem cell graft recipients.
Baseline demographic and transplantation characteristics were
compared using chi-square or Fisher exact tests for categorical data, as
appropriate. Continuous variables were compared using the Wilcoxon rank-
sum test. Relative risks of developing the separate outcomes of severe HC or
dialysis were calculated based on the presence of viruria or the degree of
viremia (high viremia versus low viremia). Analysis of covariance was used
to test the association between the peak quantitative urine or plasma PCR
viral load and eGFR at the time of BK testing, 100 days, or 365 days,
controlling for eGFR value at baseline. Quantitative viral load measurements
were logarithmically transformed to account for skewed distribution. For
mortality outcomes, survival analysis was performed using the Kaplan-
Meier method and the log-rank test for comparisons between groups. All
statistical analyses were performed using Stata 12.1 (StataCorp LP, College
Station, Texas) and SAS 9.2 (SAS Institute, Cary, NC), and a 2-sided P < .05
was considered signiﬁcant.
RESULTS
Study Population
From January 2005 to March 2012, BKV testing (urine
and/or plasma) was performed in 68 of 221 patients (30.8%)
undergoing allogeneic HSCT at our center (Figure 1). Testing
was almost exclusively performed for symptomatic HC, with
only 2 subjects having testing sent for evaluation of persis-
tent fever, both of whomwere included in the ﬁnal analyses.
Table 1
Demographic and Clinical Characteristics by BK Viremia Status
High Viremia
(N ¼ 20)
Low Viremia
(N ¼ 48)
P Value
Age, y 10.3 (5.3-17.8) 11.9 (.5-23.25) .96
Female gender 7 (35.0) 23 (47.9) .42
Underlying disease
Malignant 17 (85.0) 36 (75.0) .53
Nonmalignant 3 (15.0) 12 (25.0)
Conditioning
Myeloablative 18 (90.0) 42 (87.5) 1.0
Reduced intensity 2 (10.0) 6 (12.5)
Donor type
Matched sibling 2 (10.0) 19 (39.6) .02
Alternative 18 (90.0) 29 (60.4)
Stem cell source
Bone marrow 4 (20.0) 20 (41.7) .19
Peripheral blood 13 (65.0) 20 (41.7)
Cord blood 3 (15.0) 8 (16.7)
Values are medians with ranges in parentheses or n with percents in
parentheses. P values calculated using Fisher exact test for categorical
variables and Wilcoxon rank-sum for continuous variables.
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(69.1%) were positive in the urine. The remaining 21 subjects
had negative urine testing during the study period and
comprised the BK-negative group.
Of the 47 viruric patients, 42 underwent plasma PCR
testing for BKV, and 36 were positive. Twenty of these
viremic patients had a peak plasma PCR viral load  10,000
copies/mL (high viremia). Of the 21 patients without viruria,
17 underwent plasma PCR testing, and none was positive.
Therefore, a total of 59 patients underwent plasma testing.
The low- viremia group included subjects with peak plasma
viral loads <10,000 copies/mL, those without viremia, and
those without plasma testing but no viruria (Figure 1).
Most study subjects underwent myeloablative condi-
tioning (88.2%) for a malignant indication (77.9%) and
received a transplant from an unrelated donor (69.1%). There
were no statistically signiﬁcant differences in the clinical
characteristics of age, gender, underlying disease, condi-
tioning (myeloablative versus reduced intensity), donor type,
and stem cell source between patients with and without
viruria. Patients with high viremia were more likely to have
received grafts from alternative donors compared with those
with low viremia, but otherwise demographic and trans-
plantation characteristics were also similar between these
viremia groups (Table 1).BKV Infection Characteristics
The 47 viruric patients had a median peak urinary viral
load of 2.6 1010 copies/mL (range, 3270 to 8.21011 copies/
mL). The peak urinary viral load exceeded 1 billion copies/mL
in 38 patients (80.9%). For those patients with any viremia
(plasma PCR > 0 copies/mL) the median peak plasma load
was 12,780 copies/mL (range, 202 to 5.5  107 copies/mL).Table 2
Peak Plasma and Urine Viral Loads by Outcome
Viral load HC P Value Dialysis
Grades 0-III
(N ¼ 51)
Grade IV
(N ¼ 5)
No Dialy
(N ¼ 59)
Peak urine, copies/mL 1.25  1010 1.96  1010 .95 7.97  1
Peak plasma, copies/mL 2,378 2,460,000 <.01 2,378
Values are medians. P values calculated using Wilcoxon rank-sum tests to comparInitial BKV testing occurred at a median of day 36 (inter-
quartile range, 8 to 83 days after HSCT) in the patients with
viruria and day 24 (interquartile range, 8 to 58 days after
HSCT) in the patients without viruria (P ¼ .15).
The ﬁrst BKV urine PCR test was sent a median of 1 day
(range, 0 to 38 days) after the development of HC. A median
of 1.5 urine tests (range, 1 to 8 tests) were sent per patient,
and 24 viruric patients (51.1%) had more than 1 urine PCR
assessment. Of those with at least 2 measurements, BK
viruria was monitored over a median span of 25 days (range,
4 to 130 days). In viremic patients, the median time from
development of HC to the ﬁrst plasma test was 2 days (range,
0 to 76 days). Twenty-two viremic patients (61.1%) under-
went repeat plasma PCR testing (median, 2; range, 1 to 9)
over a median span of 23 days (range, 1 to 137 days). Forty
percent of viremic patients and 43.5% of viruric patients with
multiple measurements were monitored for a span of more
than 30 days. There were no differences in the time to the
ﬁrst urine or plasma measurement, number of samples
tested, or the span over which testing was performed
between patients with or without viruria. Patients with high
viremia had more urine (but not plasma) samples checked
(median 2 versus 1; P ¼ .046) over a longer time period
(median 44.5 days versus 11 days; P ¼ .01) than those with
low viremia.
Of patients with viruria, 18 of 47 (38.3%) received cido-
fovir to treat BKV infection. More patients with high viremia
received cidofovir (73.3%) than those that were BK positive
but with low viremia (41.2%) (P ¼ .067). In addition, more
patients with severe HC (grade IV) received cidofovir (80%)
compared with those with grades 0 to III (36%) (P ¼ .06).Severity of HC
Among the 47 patients with viruria, 39 (83.0%) had HC
grade II or worse, and 5 (10.6%) had severe HC (grade IV).
Two other patients had BK testing for evaluation of persistent
fever, and 1 patient was tested for indeterminate reasons.
Severe HC was more likely in patients with high viremia as
compared with those with low viremia (21.1% versus 2.2%,
respectively; P ¼ .023). Although the peak plasma viral load
in patients with severe HC was quantitatively and signiﬁ-
cantly higher than in patients with lower grade HC (P¼ .004),
the peak urine viral load was not associated with the grade of
HC (P ¼ .95) (Table 2).Kidney Injury
In all 68 patients undergoing BKV PCR testing, serum
creatinine-based eGFR decreased from a median of 113.4 mL/
min/1.73 m2 at baseline to 102.7 mL/min/1.73 m2 at day 100
(P ¼ .03) and to 97.0 mL/min/1.73 m2 at day 365 (P < .001).
The absolute levels of eGFR and mean percent changes from
baseline based on BKV status are summarized in Table 3.
There were no differences in mean percent change from
baseline eGFR as measured at time of BKV testing, day 100,P Value TRM P Value
sis Dialysis
(N ¼ 7)
Alive at 1 y
(N ¼ 52)
Dead at 1 y
(N ¼ 16)
09 2.86  1010 .59 5.43  109 1.31  1010 .73
26,110 .23 2476 1826.5 .79
e viral loads for each outcome. TRM indicates transplant-related mortality.
Table 3
Serum creatinine-eGFR by BK Viruria and Viremia Status
Viruria Status Viremia Status
Viruria No Viruria High Viremia Low Viremia
eGFR % D eGFR % D eGFR % D eGFR % D
Baseline 119.4 d 110.1 d 113.0 d 117.5 d
Time of BK 108.5 6.8 105.2 3.4 110.7 1.8 109.7 5.2
Day þ100 103.7 1.3 96.9 9.4 126.7 þ14.6 104.5 10.9
Day þ365 92.9 15.7 97.6 12.1 102.2 6.3 97.3 18.0
eGFR estimated with the updated Schwartz formula. eGFR values presented as median mL/min/1.73m2. %D are the mean percent changes in eGFR relative to
baseline (ie, a negative value indicates a decrement in eGFR).
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there were was no signiﬁcant decrement in eGFR at the same
time intervals in those with high versus low viremia. At day
100, the mean percent decrement in eGFR was signiﬁcantly
higher in low viremia than high-viremia patients, contrary to
expectations, but this effect was abrogated by day 365.
Five patients with viruria (10.6%) and 2 patients with-
out viruria (9.5%) required dialysis at any point post-HSCT
(P ¼ .92). High viremia was not associated with the need
for dialysis (P ¼ .43). There was a trend toward a higher peak
plasma and urine viral load in patients requiring dialysis, but
neither of these differences reached statistical signiﬁcance
(Table 2). The results were the same when subjects in whom
dialysis was initiated before ﬁrst BKV PCR (n ¼ 3) were
excluded from the analysis (data not shown).Additional Transplantation Outcomes
Table 4 summarizes additional transplantation outcomes
for the study population by BK viremia status. There was
a trend toward more grade III to IV acute GVHD, chronic
GVHD, and veno-occlusive disease in high-viremia patients
compared with those with low viremia, although none of
these differences reached statistical signiﬁcance. Similarly,
there was a nonsigniﬁcantly higher incidence of a concomi-
tant viral infection (CMV, adenovirus, either virus, or both
viruses) in high versus low- viremia patients.Table 4
Transplantation Outcomes by BK Viremia Status
High Viremia
(N ¼ 20)
Low Viremia
(N ¼ 48)
P Value
Engraftment, days
ANC > 500 15 (11-19) 17 (11-27) .12
Platelets > 20K 19 (16-33) 20 (11-44) .69
Acute GVHD incidence
Any 12 (66.7) 27 (62.8) 1.0
Grades II-IV 10 (50.0) 19 (39.6) .59
Grades III-IV 7 (35.0) 10 (20.8) .18
Chronic GVHD incidence
Any 7 (41.2) 9 (27.3) .35
Extensive 4 (20.0) 6 (12.5) .47
VOD 4 (20.0) 3 (6.3) .18
Virus
CMV 8 (40.0) 10 (20.8) .13
Adenovirus 5 (25.0) 6 (12.5) .28
Either 11 (55.0) 14 (29.2) .06
Both 2 (10.0) 2 (4.2) .58
TRM at 1 year 25.0% 22.9% 1.0
OS at 1 year 65.0% 75.0% .55
Values aremedianswith interquartile ranges inparenthesesornwithpercents
in parentheses. P values calculated using Fisher exact test for categorical
variables, Wilcoxon rank-sum for continuous variables, and log-rank test for
survival. ANC indicates absolute neutrophil count; OS, overall survival; TRM,
transplantation-related mortality; VOD, veno-occlusive disease.Overall survival at 1 year did not differ signiﬁcantly
between those with or without viruria (71.1% and 65.0%,
respectively) or between the high and low-viremia groups
(65.0% and 75.0%, respectively). Neither urinary nor plasma
peak viral load predicted the 1-year overall survival rate, and
the median urine and plasma peak viral loads were similar
between subjects that survived to 1 year post-HSCT and
those that did not (Table 2). Similarly, there were no statis-
tically signiﬁcant differences between transplantation-
related mortality based on either viruria or high viremia
status (Table 4).
DISCUSSION
BKV infection is known to be associated with HC in adults
and children undergoing HSCT [5,6] and may also be asso-
ciated with direct kidney injury [11-16], as seen in kidney
transplantation recipients [2].We found that viremia, but not
viruria, was associated with more severe bladder injury
(higher grade HC) in a retrospective cohort of children after
allogeneic HSCT. In contrast, neither viremia nor viruria was
associated with lower serum creatinine-eGFR, the need for
dialysis, or mortality. The strengths of our analysis include
follow-up to 1 year; assessment of kidney, bladder, and
overall outcomes; and the inclusion of a large pediatric
allogeneic HSCT population. Our study was limited by the
retrospective reporting of clinical data and nonsystematic
measurement of BK virus infection in all subjects.
The timing and prevalence of BKV-related HC in our
patients is consistent with prior reports [9,16]. The magni-
tude of the PCR-measured viral loads in the urine and plasma
was also similar to a study in children after HSCT [16]. We
found no association between acute GVHD and the timing of
engraftment and BKV infection, although there was a trend
toward more severe acute GVHD in patients with high
viremia. Others have speculated that BKV infection in HSCT
recipients is related not only to the degree of immunosup-
pression but also to direct tissue injury [22]. Because GVHD is
associated with both augmented immunosuppression and
tissue damage [23], one might expect a higher rate of GVHD
in those with BKV infection. The high rate of GVHD in both
viruric and nonviruric patients may explain our inability to
detect an effect, possibly because most transplantations
were high risk (alternative donors) compared with the
general allogeneic transplantation population.
The threshold for deﬁning “high viremia” as a PCR viral
load  10,000 copies/mL was originally described in kidney
transplantation recipients with biopsy-proven nephropathy
[2]. In children receiving HSCT, high viremia has been asso-
ciatedwith the need for invasive procedures for HC, increased
post-HSCT creatinine, dialysis, and end-stage renal disease
[16]. We also observed an association between high viremia
and the severity of HC. Prior studies have documented BK
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[7-9,24,25]. To our knowledge, however, only 1 study [16] has
identiﬁed BK viral load as predictive of the severity of bladder
injury after HC. The present study included children under-
going transplantation primarily for a malignant indication,
potentially broadening the applicability of the ﬁndings to
a wider group of patients.
We were unable to detect an association between peak
plasma PCR  10,000 copies/mL and creatinine-estimated
kidney function or the need for dialysis. Subjects requiring
dialysis did trend toward having a higher median peak
plasma viral load, suggesting our study may have been
underpowered to detect this difference. Peak urine viral
loads were not associated with any outcome measure,
a ﬁnding consistent with prior reports from both the adult
and pediatric HSCT populations [16,25].
Only 2 studies have reported measures of kidney function
in patients with BKV infection after HSCT [15,16]. Both
studies found an association between BK viremia and im-
paired kidney function, measured either by absolute serum
creatinine level [15] or by the maximum fold increase in
serum creatinine relative to pretransplantation baseline [16],
without calculating subjects’ eGFR. In our population,
neither viruria nor the degree of viremiawas associated with
a need for post-transplantation dialysis or a decrement in
baseline eGFR, either at the time of BKV infection, day 100, or
day 365.
Several factors may account for these discrepant ﬁndings.
First, the prevalence of severe HC we observed is lower than
that reported by others. Because severe HC is often associ-
ated with obstructive and nephrotoxic (eg, use of antivirals)
kidney injury, differences in the rate and severity of HC
across studies may explain the variable reporting of renal
outcomes such as eGFR and the need for dialysis. Second,
because kidney injury is multifactorial after HSCT, residual
confounding of unmeasured exposures (including antibi-
otics, calcineurin inhibitors, and other infections) may also
vary between different study populations. Third, by esti-
mating kidney function at deﬁned time periods, it is possible
we missed the window of kidney injury, whereas other
studies have reported the peak creatinine at any point after
BKV detection compared with the pretransplantation base-
line. Fourth, the differences in the study population may
inﬂuence kidney outcomes and the risk for severe BKV
infection; speciﬁcally, our cohort contained fewer patients
who underwent transplantation for nonmalignant indica-
tions andmore peripheral blood stem cell and umbilical cord
grafts. Finally, the paucity of patients requiring dialysis and
differences in outcome deﬁnitions (overall, transplantation-
related, and BK-attributable mortality) limits our ability to
make comparisons to previous studies.
The change in renal function over time observed in
our study may be illustrative. Although not signiﬁcant, it
appeared there was only a modest decrease in eGFR at day
100 but a more pronounced decrease between day 100 and
day 365. This may suggest it takes several months for
patients with BKV infection to demonstrate changes in their
kidney function. We were unable to directly evaluate this
possibility because viral load measurements in viremic
patients were made in a nonsystematic fashion, and only
a portion of viremic patients had longitudinal surveillance of
plasma viral loads.
Although serum creatinine is an established method of
estimating kidney function, its concentration is highly
dependent on muscle mass, potentially limiting its utility inchildrenwho have a high risk of deconditioning (after HSCT).
Consistent with prior reports, it is possible serum creatinine
overestimates GFR in this population [26]. Although this is
the ﬁrst study to calculate eGFR in children with BKV infec-
tion after HCT, where height is used as a proxy for muscle
mass, this adjustment is not exact. Additionally, we used
a single measurement of height (taken pretransplantation) to
estimate GFR throughout the transplantation period, adding
to the inaccuracy of GFR estimation in growing children.
However, the relative paucity of vertical growth experienced
during the immediate post-HSCT period likely offsets this
factor. Future studies using muscle masseindependent
methods to estimate kidney function may better deﬁne the
degree of renal impairment after HSCT, both in those with
and without BKV infection. One such method, serum cystatin
C, is gaining more widespread use [26,27].
Importantly, our cohort consisted of only patients having
PCR testing performed for a clinical indication, raising the
possibility these were the sickest patients. Indeed, the
observed incidence of acute GVHD exceeded that typically
seen in our general allogeneic HSCT population. Only larger
studies using prospective surveillance for BKV infection in all
HSCT recipients will be able to address this limitation. In
addition, as prior studies have documented peak BK viral
loads in urine and plasma that preceded the development of
HC [24], it is possible that we missed a period of more severe
BKV infection and therefore misclassiﬁed patients by degree
of viruria or viremia.
In conclusion, we observed a high prevalence of BKV-
associated HC in children undergoing allogeneic HSCT. The
severity of HC correlated with the degree of BKV viremia but
not viruria. High viremia was more common in children
receiving a transplant from an alternative donor. Consistent
with kidney transplantation guidelines, BK viremia may be
more speciﬁc for clinical disease in HSCT recipients, as
compared with BK viruria [28]. In patients with HC or
unexplained kidney injury after HSCT, we suggest initial
testing of BKV with plasma and urine PCR assays to establish
the diagnosis of BKV infection. Subsequently, if further
monitoring is clinically indicated, testing should continue
only with plasma. The development of targeted prophylaxis
and/or treatment strategies may support the beneﬁt of this
monitoring approach in an effort to decrease the burden of
severe HC. Although BKV infection was not associated with
renal outcomes in the present study, future research is
needed to address the impact of using more accurate
measures of kidney function in this population at high risk of
low muscle mass.
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